Shopping Cart

Your shopping cart is currently empty

DN-1289

Name: DN-1289
Brand: TargetMol
SKU: T73457
Price: 78 USD
Availability: InStock
Rating: 5 (10 reviews)

😃Good

Catalog No. T73457

DN-1289 is an orally available, blood-brain barrier-crossing, selective and potent inhibitor with an IC50 value of 17 nM for di-leucine zipper kinase (DLK) and 40 nM for leucine zipper-bearing kinase (LZK).DN-1289 significantly inhibited optic nerve crush (ONC)-induced p-c-Jun in a mouse model.

DN-1289

😃Good

Purity: 98.56%

Catalog No. T73457

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$78	In Stock	In Stock
5 mg	$189	In Stock	In Stock
10 mg	$297	In Stock	In Stock
25 mg	$619	In Stock	In Stock
50 mg	$993	In Stock	In Stock
100 mg	$1,590	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

Questions

Batch Information

Select Batch

Purity:98.56%

ee:100%

Appearance:Solid

Color:White

Resource Download

COA CSFC FNMR HNMR LCMS ORP

Product Introduction

Bioactivity

Description	DN-1289 is an orally available, blood-brain barrier-crossing, selective and potent inhibitor with an IC50 value of 17 nM for di-leucine zipper kinase (DLK) and 40 nM for leucine zipper-bearing kinase (LZK).DN-1289 significantly inhibited optic nerve crush (ONC)-induced p-c-Jun in a mouse model.
In vitro	DN-1289 (Compound 14) (0.1, 0.3, and 1 μM; 0-20 h) can block the neurite degeneration induced by nerve growth factor (NGF) withdrawal in dorsal root ganglion (DRG) neurons[1]. DN-1289 (0.1, 0.3, and 1 μM; 0-20 h) inhibits the activation of caspases, apoptotic protease, in NGF withdrawal-induced apoptosis in DRG neurons[1].
In vivo	DN-1289 (Compound 14) demonstrates good tolerance in a mouse model at doses of 100 mg/kg and 150 mg/kg administered via intraperitoneal injection once daily for 10-15 days[1]. DN-1289 (150 mg/kg; oral administration; twice daily for 10 days) inhibits c-Jun phosphorylation in the acute optic nerve crush (ONC) injury model[1].

Chemical Properties

Molecular Weight	441.38
Formula	C₁₈H₁₉F₄N₇O₂
Smiles	NC1=C(OC(F)F)N=C(C2=NC(N3[C@@H]4CO[C@H](C3)C4)=NC(N5CC(F)(CC5)F)=C2)C=N1

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 55 mg/mL (124.61 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.53 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2656 mL	11.3281 mL	22.6562 mL	113.2811 mL
5 mM	0.4531 mL	2.2656 mL	4.5312 mL	22.6562 mL
10 mM	0.2266 mL	1.1328 mL	2.2656 mL	11.3281 mL
20 mM	0.1133 mL	0.5664 mL	1.1328 mL	5.6641 mL
50 mM	0.0453 mL	0.2266 mL	0.4531 mL	2.2656 mL
100 mM	0.0227 mL	0.1133 mL	0.2266 mL	1.1328 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc